AR and prostate cancer: The results presented herein demonstrate that the NGGAs, VNPP414 and VNPP433-3β, are promising anti-prostate cancer molecules and are more effective than their parent molecule, Gal and the FDA-approved anti-AR drug, enzalutamide.